share_log

贝康医疗-B(02170)拟8500万元收购星博生物的51%股权

Baycom Medical-B (02170) plans to acquire 51% stake in Xingbo Biology for 85 million yuan.

Moomoo 24/7 ·  Nov 3, 2021 00:25
Bacon Medical-Borex 02170 announced that on November 3, 2017, the company entered into an investment agreement with the seller Xue Zhigang. D holding 20.84% of the shares, Hawk Investment. 5.45% and Hu Xiling. 24.71% of the shares and Xingbo Biological. Upon completion of the acquisition, Xingbo Bio will become a non-wholly owned subsidiary of the company. It is reported that Xingbo Biology is a limited company established in China. It is mainly engaged in the research, development, production and sales of assisted reproductive technology diagnosis and treatment products, providing a comprehensive solution for the accurate evaluation of the fertility of men of childbearing age in China. According to the announcement, in view of Xingbo's strategic layout of the strong product portfolio of China's reproductive genetic medical device market, strong R & D and marketing capabilities and experienced senior management team on China's broader reproductive genetic market and the overall medical equipment industry, the company is optimistic about the development prospects and development of Xingbo Biology. The company believes that Xingbo's biological business can provide synergy for the group's business, while the development of Xingbo biological and research products can further enrich the company's product supply in markets that have not yet been launched in China.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment